Prostamax vs Vesilute
Moderate Research vs Moderate Research
synergistic Both target prostate/urogenital health; can be combined for comprehensive support.
Molecular Data
Prostamax Vesilute
Weight 473 Da 262 Da
Half-life Not established Not established
Chain 4 amino acids 2 amino acids
Type Tetrapeptide bioregulator Dipeptide bioregulator
Key Benefits
Prostamax
01 Reduces prostate inflammation
02 Decreases prostatic swelling
03 Reduces vascular congestion (hyperemia)
04 Decreases immune cell infiltration
05 Reduces scarring in prostate tissue
06 Promotes chromatin decondensation
07 Reactivates age-repressed genes
08 Improves lymphocyte function
Vesilute
01 Supports bladder and urinary tract function
02 May improve prostate health in men
03 Regulates smooth muscle function
04 Enhances pelvic tissue blood flow
05 Supports cellular regeneration
06 Part of comprehensive Khavinson bioregulator protocols
07 Well-tolerated in research
08 Oral bioavailability as small dipeptide
Dosing Protocols
Prostamax
10-20mg daily / Daily for 10-20 days per cycle
Research protocol 10 mg Daily for 10-15 days
Vesilute
10-20 mg per day / Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Standard protocol 10-20 mg Daily for 10-20 days
Maintenance 20 mg 2-3 cycles yearly
Side Effects
Prostamax
Generally well-tolerated
Minimal side effects reported
Vesilute
Generally well-tolerated
Injection site reactions (mild, if injectable)
Minimal reported side effects
Contraindications
Prostate cancer (consult oncologist)
Known hypersensitivity
Pregnancy (not applicable)
Known hypersensitivity to peptide components
Active urinary tract infection (treat first)
Pregnancy or breastfeeding
Prostate cancer (consult physician)
Research Evidence
Prostamax Vesilute
Status Moderate Research Moderate Research
References 4 studies 3 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.